Results 131 to 140 of about 5,286 (232)

Isoform of Bruton's tyrosine kinase (BTK) protein

, 2008
The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR ...
LAVITRANO, MARIALUISA, GRASSILLI, EMANUELA, Helin, K.   +2 more
openaire   +2 more sources

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract We report primary analysis results from the Phase 3 PERSPECTIVE study comparing ibrutinib + rituximab versus placebo + rituximab in patients with previously untreated follicular lymphoma requiring treatment per Groupe d'Etude des Lymphomes Folliculaires criteria who were ineligible for chemoimmunotherapy due to age and/or comorbidities.
David Belada, Faithlore P. Gardner, Ana C. de Oliveira, Juan‐Manuel Sancho, Elza Lomaia, David Wright, Mehmet Turgut, Elena Martynova, Zsolt Lázár, Bertrand Anz, Ming‐Chung Wang, Wojciech Legiec, Stephen Opat, Junvie Pailden, Hillary M. Peltier, Emerenziana Marturano, James P. Dean, Ian W. Flinn   +17 more
wiley   +1 more source

Control of erythropoiesis by erythropoietin and stem cell factor: a novel role for Bruton's tyrosine kinase

, 2004
Erythropoietin (Epo) and stem cell factor (SCF) are essential factors in the control of survival, expansion and differentiation of erythroid progenitors.
Schmidt, Uwe, von Lindern, Marieke, Beug, Hartmut, Hartmut Beug, Marieke von Lindern, Uwe Schmidt   +5 more
core   +1 more source

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract Previous editions of the European guidelines for the management of chronic lymphocytic leukemia (CLL) were developed by experts in CLL under the auspices of the European Society for Medical Oncology (ESMO). These previous editions have served as a reference text for many physicians caring for patients with CLL.
Barbara Eichhorst, Paolo Ghia, Francesc Bosch, Ruth Clifford, Michael Gregor, Romain Guieze, Arnon P. Kater, Carsten U. Niemann, Sarka Pospisilova, Tadeusz Robak, Anna Schuh, Kostas Stamatopoulos, Tamar Tadmor, Nick York   +13 more
wiley   +1 more source

Image_5_Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.JPEG

, 2018
Bruton's tyrosine kinase (Btk) has a key role in the signaling pathways of receptors essential for the B lymphocyte response. Given its implication in B cell-related immunodeficiencies, leukemias/lymphomas and autoimmunity, Btk is studied intensely and ...
Sara Roman-Garcia (5724011), Rudi W. Hendriks (392253), Yolanda R. Carrasco (443116), Sara V. Merino-Cortes (5724014), Sofia R. Gardeta (5724017), Marjolein J. W. de Bruijn (519862)   +5 more
core   +1 more source

Bruton's tyrosine kinase inhibition for the treatment of allergic disorders

Annals of Allergy, Asthma & Immunology
IgE signaling through its high-affinity receptor FcεRI is central to the pathogenesis of numerous allergic disorders. Oral inhibitors of Bruton's tyrosine kinase (BTKis), which are currently Food and Drug Administration-approved for treating B cell malignancies, broadly inhibit the FcεRI pathway in human mast cells and basophils, and therefore may be ...
Erica V. Lin, Ragha V. Suresh, Melanie C. Dispenza   +2 more
openaire   +2 more sources

Role(s) of IL-2 inducible T cell kinase and Bruton's tyrosine kinase in mast cell response to lipopolysaccharide

, 2016
Mast cells play critical roles during immune responses to the bacterial endotoxin lipopolysaccharide (LPS) that can lead to fatal septic hypothermia [1–3].
Avery August, Weishan Huang, August, Avery, Huang, Weishan   +3 more
core   +1 more source

Recurrent Genomic Alterations in BCRi‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up

American Journal of Hematology, Volume 101, Issue 7, Page 1516-1521, July 2026.
Jennifer A. Woyach, Relja Popovic, Emily L. Rossi, Sanjana Singh, Toshihiko Oki, Tanya S. Rosenberg, Chen Qian, Michael Moran, Zihuan Liu, Michelle Boyer, Jeffrey Jones, Richard R. Furman, William Wierda, Jason Gotlib, Stephen J. Schuster, Brenda Chyla, Matthew S. Davids   +16 more
wiley   +1 more source

Image_1_Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.PDF

, 2018
Bruton's tyrosine kinase (Btk) has a key role in the signaling pathways of receptors essential for the B lymphocyte response. Given its implication in B cell-related immunodeficiencies, leukemias/lymphomas and autoimmunity, Btk is studied intensely and ...
Sara Roman-Garcia (5724011), Rudi W. Hendriks (392253), Yolanda R. Carrasco (443116), Sara V. Merino-Cortes (5724014), Sofia R. Gardeta (5724017), Marjolein J. W. de Bruijn (519862)   +5 more
core   +1 more source

Treatment Outcomes and Overall Survival of Patients With B‐Cell Prolymphocytic Leukemia

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction B‐cell prolymphocytic leukemia (B‐PLL) is a rare, aggressive leukemic B‐cell malignancy historically associated with poor outcomes and recently reclassified in the WHO Fifth Edition but retained as a distinct entity in the ICC.
Daniel A. Ermann, Victoria A. Vardell, Lindsey Fitzgerald, Allison Bock, Harsh Shah, Boyu Hu, Deborah M. Stephens   +6 more
wiley   +1 more source